Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Nat Genet. 2016 Feb 1;48(3):273–282. doi: 10.1038/ng.3500

Figure 6. MYB-QKI fusion protein and truncated MYB are oncogenic.

Figure 6

a. In vitro cell proliferation (number of cells relative to baseline) of mNSCs overexpressing eGFP or truncated MYBtrexons1–9. The mean values for five independent pools are depicted. Error bars, s.e.m.

b. Tumor growth following flank injections of NIH3T3 cells overexpressing MYB, MYBtrexons1–15 or a vector control. The means of five measurements are depicted. Error bars, s.e.m. Representative images are shown for intracranial mNSC-MYB-QKI6 tumors.

c. In vitro cell proliferation of mNSCs that overexpress MYB-QKI5 (short), MYB-QKI6 (short) or eGFP control. The means of five independent pools are depicted. Error bars, s.e.m.

d. Tumor growth following flank injections of NIH3T3 cells overexpressing MYB, MYB-QKI5 (long), MYB-QKI6 (long) or vector control. The mean of five measurements is depicted. Error bars, s.e.m. Representative images are shown of intracranial mNSC–truncated MYB tumors.

e. Hematoxylin and eosin analysis of severe combined immunodeficient (SCID) mouse brain after striatal injections with mNSCs expressing eGFP, truncated MYB, MYB-QKI5 or MYB-QKI6. Scale bars, 2 mm (top) and 50 ?m (bottom).

f. Kaplan-Meier survival analysis of orthotopic SCID mice injected with mNSCs overexpressing truncated MYB, MYB-QKI5 or MYB-QKI6 that develop tumors with short latency in comparison to mice injected with mNSCs expressing eGFP, which never develop tumors (**P < 0.05).